Respiratory Syncytial Virus (RSV) Vaccine: AREXVY AREXVY combines the RSVPreF3 antigen with the AS01E adjuvant system, designed to induce rapid and long-lasting humoral and cellular immune responses, providing protection for older adults. This vaccine is suitable for individuals aged 60 and above and is effective in preventing lower respiratory tract diseases caused by RSV. It demonstrates outstanding preventive efficacy in this age group: 82.6% efficiency in preventing lower respiratory tract diseases caused by RSV. 94.6% efficiency in preventing RSV-related lower respiratory tract diseases among individuals with at least one underlying condition, such as chronic obstructive pulmonary disease (COPD), asthma, any chronic respiratory or lung disease, chronic heart failure, diabetes, and advanced liver or kidney disease (endocrine metabolic conditions). AREXVY aims to enhance respiratory health and protect vulnerable populations from the severe impacts of RSV infections.